Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Porfimer→

Porfimer Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
87806-31-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Porphyrin-based photosensitiserphotodynamic therapy antineoplastic agent
Mechanism of action
After intravenous administration, porfimer accumulates in selected tissues. Exposure to appropriate wavelength light generates reactive oxygen species, causing local cellular injury, vascular damage and tumour necrosis.
Indications / reported uses
  • Photodynamic therapy for microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated
  • Palliation of symptoms and obstruction in patients with completely or partially obstructing endobronchial NSCLC; treatment requires light activation and careful protection from photosensitivity

Sources: US DailyMed — PHOTOFRIN (porfimer sodium) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Porfimer Environmental Risk Assessment (ERA) (the Porfimer ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.